Protalix BioTherapeutics, Inc. (AMEX:PLX) biopharmaceutical firm, is expected to report third quarter earnings results, before market open, on Thursday 29th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.08 per share.
Looking ahead, the full year loss are expected at $ 0.19 per share on the revenues of $ 61.27 million.
Previous Quarter Performance
Protalix BioTherapeutics, Inc. reported loss for the second quarter of $ 0.13 per share, from the revenue of $ 10.97 million. The quarterly revenues contracted 10.45 percent compared with the same quarter last year. According to street consensus, PLX was expected to report 2Q20 loss of $ 0.20 per share from revenue of $ 10.87 million. The bottom line results beat street analysts by $ 0.07 or 35.00 percent, at the same time, top line results outshined analysts by $ 0.10 million or 0.92 percent.
Stock Performance
Shares of Protalix BioTherapeutics, Inc. traded up $ 0.02 or 0.57 percent on Wednesday, reaching $ 3.55 with volume of 54.90 thousand shares. Protalix BioTherapeutics, Inc. has traded high as $ 3.57 and has cracked $ 3.44 on the downward trend
According to the previous trading day, closing price of $ 3.55, representing a 85.79 % increase from the 52 week low of $ 1.90 and a 27.52 % decrease over the 52 week high of $ 4.87.
The company has a market capital of $ 118.35 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Protalix BioTherapeutics, Inc. will be hosting a conference call at 8:30 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.protalix.com
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which has completed phase IIa clinical trials for the treatment of ulcerative colitis.
